Erythropoietin-induced, antibody-mediated pure red cell aplasia

被引：0

作者：

Rossert, J ^{[1
]}

Maroni, B ^{[1
]}

Aljama, P ^{[1
]}

Casadevall, N ^{[1
]}

Cooper, M ^{[1
]}

Delage, R ^{[1
]}

Eckardt, KU ^{[1
]}

de Francisco, AML ^{[1
]}

Hörl, W ^{[1
]}

Jelkmann, W ^{[1
]}

Johnson, D ^{[1
]}

Locatelli, F ^{[1
]}

Macdougall, I ^{[1
]}

Nissenson, AR ^{[1
]}

Pollock, C ^{[1
]}

Schellekens, H ^{[1
]}

Thorpe, R ^{[1
]}

Toffelmire, E ^{[1
]}

机构：

[1] Hop Europeen Georges Pompidou, F-75015 Paris, France

来源：

EUROPEAN JOURNAL OF CLINICAL INVESTIGATION | 2005年 / 35卷

关键词：

anaemia; aplasia; diagnosis; epoetin; immunogenicity; therapy;

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Pure red cell aplasia (PRCA) is a rare haematological condition that is characterized by severe aregenerative anaemia due to an almost complete cessation of red blood cell production. While antibody-mediated PRCA was extremely rare before 1998, the incidence of this disorder increased sharply after 1998 in patients receiving subcutaneous epoetin alfa produced by Ortho-Biotech and marketed outside the USA. The diagnosis of antibody-mediated PRCA relies mostly on the results of bone marrow biopsy or aspirate, which shows an absence of erythroid precursors and/or red cell maturation arrest while counts of white cell and platelet precursors are normal, and on the identification of circulating antierythropoietin antibodies. Retrospective analysis of PRCA cases has shown that immunosuppressive therapy can induce a disappearance of anti-erythropoietin antibodies in most patients.

引用

页码：95 / 99

页数：5

共 32 条

[1]

BERGREM H, 1993, ERYTHROPOIETIN, P265

[2] Pure red-cell aplasia and antierythropoietin antibodies in patients treated with recombinant erythropoietin. [J].